Effect of cyclophosphamide administration on the activity and relative content of hepatic P4502D1 in rat

References

• Brosen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 1989; 36: 537–547
   PubMed Web of Science ®Google Scholar
• Daly A. K., Cholerton S., Gregory W., Idle J. R. Metabolic polymorphisms. Pharmacology and Therapeutics 1993; 57: 129–160
   PubMed Web of Science ®Google Scholar
• Evans W. E., Relling M. V., Rahman A., McLeod H. L., Scott E. P., Lin J. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. Journal of Clinical Investigation 1993; 91: 2150–2154
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. Control of constitutively-expressed developmentally-activated rat hepatic cytochrome P450 genes. Keio Journal of Medicine 1992; 41: 68–75
   PubMedGoogle Scholar
• Gonzalez F. J., Matsunaga T., Nagata K., Meyer U. A., Nebert D. W., Pastewka J., Kozak C. A., Gillette J., Gelboin H. V., Hardwick J. P. Debrisoquine 4-hydroxylase: Characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 1987; 6: 149–161
   PubMedGoogle Scholar
• Gonzalez F. J., Vilbois F., Hrdwick J. P., McBride O. W., Nebert D. W., Gelboin H. V., Meyer U. A. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 1988; 2: 174–179
   PubMedGoogle Scholar
• Kerry N. L., Somogyi A. A., Mikus G., Bochner F. Primary and secondary oxidative metabolism of dextromethorphan: in vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes. Biochemical Pharmacology 1993; 45: 833–839
   PubMed Web of Science ®Google Scholar
• Kitada M., Sakamoto K., Rikihisa T., Kanakubo Y. The interaction between two forms of cytochrome P-450 during drug oxidation in the reconstituted system containing limited amount of NADPH-cytochrome P-450 reductase. Biochemical Pharmacology 1984; 33: 3971–3976
   PubMed Web of Science ®Google Scholar
• Küpfer A., Schmid B., Preisig R., Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; ii: 517–518
   Google Scholar
• Larrey D., Distlerath L. M., Dannan G. A., Wilkinson G. R., Guengerich F. P. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23: 2787–2795
   PubMed Web of Science ®Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Lear L., Nation R. L., Stupans I. Influence of morphine concentration on detergent activation of rat liver morphine-UDP-glucuronosyltransferase. Biochemical Pharmacology 1991; 42(Suppl.)S55–60
   PubMedGoogle Scholar
• Lear L., Nation R. L., Stupans I. Effects of cyclophosphamide and adriamycin on rat hepatic microsomal glucuronidation and lipid peroxidation. Biochemical Pharmacology 1992; 44: 747–753
   PubMed Web of Science ®Google Scholar
• LeBlanc G. A., Waxman D. J. Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Research 1990; 50: 5720–5726
   PubMed Web of Science ®Google Scholar
• Le Guellec C., Lacarelle B., Catalin J., Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemotherapy and Pharmacology 1993; 32: 491–495
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Moereels H. The sequence homologies of cytothromes P-450 and active-site geometries. Journal of Computer-Aided Molecular Design 1992; 6: 235–252
   PubMed Web of Science ®Google Scholar
• McClure M. T., Stupans I. Investigation of the mechanism by which cyclophosphamide alters cytochrome P450 in male rats. Biochemical Pharmacology 1992; 43: 2655–2658
   PubMed Web of Science ®Google Scholar
• McClure M. T., Stupans I. Hormonal perturbation as a possible mechanism for the alteration of cytochrome P450 by cyclophosphamide. Biochemical Pharmacology 1995; 49: 1827–1836
   PubMed Web of Science ®Google Scholar
• Miwa G. T., West S. B., Lu A. Y. H. Stidies on the rate-limiting enzyme component in the microsomal monooxygenase system: incorporation of purified NADPH-cytochrome c reductase and cytochrome P-450 into rat liver microsomes. Journal of Biological Chemistry 1978; 253: 1921–1929
   PubMed Web of Science ®Google Scholar
• Mortimer Ö., Lindström B., Laurell H., Bergman U., Rane A. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. British Journal of Clinical Pharmacology 1989; 27: 223–227
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Porter T. D., Coon M. J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. Journal of Biological Chemistry 1991; 266: 13469–13472
   PubMed Web of Science ®Google Scholar
• Relling M. V., Evans W. E., Fonné Pfster R., Meyer U. A. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquine and mephenytoin hydroxylase, in human liver microsomes. Cancer Research 1989; 49: 68–71
   PubMedGoogle Scholar
• Rizzardini M., Ferraroli A., Dal Flume D., Cantoni L. Cyclophosphamide-impaired regulation of hepatic heme metabolism. Experientia 1984; 40: 1390–1392
   PubMedGoogle Scholar
• Sladek N. E., Powers J. F., Grage G. M. Half-life of oxazaphosphorines in biological fluids. Drug Metabolism and Disposition 1984; 12: 553–559
   PubMedGoogle Scholar
• Soucek P., Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1992; 22: 83–103
   PubMed Web of Science ®Google Scholar
• Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, USA 1979; 76: 4350–4354
   PubMed Web of Science ®Google Scholar
• Treluyer J., Jacqz-Aigrain E., Alvarez F., Cresteil T. Expression of CYP2D6 in developing human liver. European Journal of Biochemistry 1991; 202: 583–588
   PubMedGoogle Scholar
• Truan G., Cullin C., Reisdorf P., Urban P., Pompon D. Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and cytochrome b5. Gene 1993; 125: 49–55
   PubMedGoogle Scholar
• Yamamoto A M., Cresteil D., Boniface O., Clerc F. F., Alverez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). European Journal of Immunology 1993a; 23: 1105–1111
   PubMed Web of Science ®Google Scholar
• Yamamoto A. M., Mura C., De Lemos-Chiarandini C., Krishnamoorthy R., Alverez F. Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes. Clinical and Experimental Immunology 1993b; 92: 381–390
   PubMed Web of Science ®Google Scholar
• Zysset T., Zeugin T., Küpfer A. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochemical Pharmacology 1988; 37: 3155–3160
   PubMed Web of Science ®Google Scholar